Fig. 5.

Effects of palbociclib on disease progression in the MCT rat model of pulmonary arterial hypertension. a Scheme of animal treatments. Echocardiograms were recorded at baseline, 21 days after MCT administration and again on day 35 after a 14-day period of treatment with 75 mg/kg body weight palbociclib (or placebo) daily by gavage. b–l On day 35, hemodynamics and cardiac function were assessed in vivo 14 days after treatment with palbociclib (MCT + Palbo, n = 5). Similarly, healthy rats (Healthy, n = 6) and animals injected with MCT and placebo (MCT, n = 5) were used as control groups. Data are presented as mean ± SEM and statistical analysis was performed using one-way ANOVA with Newman–Keuls post-hoc test for multiple comparisons; *p < 0.05, **p < 0.01, ***p < 0.001 for MCT + Palbo versus MCT; ^§ p< 0.05, ^§§p < 0.01, ^§§§p < 0.001, ^§§§§p < 0.0001 for MCT + Palbo versus healthy; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001, ^####p < 0.0001 for healthy versus MCT. Source data are provided as a Source Data file